UBX
Income statement / Annual
Last year (2024), Unity Biotechnology, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Unity Biotechnology, Inc.'s net income was -$25.99 M.
See Unity Biotechnology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$236.00 K |
$4.78 M |
$0.00 |
$0.00 |
$0.00 |
$1.38 M |
$0.00 |
| Cost of Revenue |
$867.00 K
|
$19.70 M
|
$2.18 M
|
$2.88 M
|
$3.45 M
|
$2.66 M
|
$2.18 M
|
$37.37 M
|
$153.00 K
|
| Gross Profit |
-$867.00 K
|
-$19.70 M
|
-$1.94 M
|
$1.90 M
|
-$3.45 M
|
-$2.66 M
|
-$2.18 M
|
-$35.99 M
|
-$153.00 K
|
| Gross Profit Ratio |
0
|
0
|
-8.24
|
0.4
|
0
|
0
|
0
|
-26.04
|
0
|
| Research and Development Expenses |
$13.01 M
|
$20.80 M
|
$36.86 M
|
$38.39 M
|
$67.31 M
|
$70.96 M
|
$58.91 M
|
$37.37 M
|
$13.71 M
|
| General & Administrative Expenses |
$15.46 M
|
$18.77 M
|
$20.95 M
|
$23.06 M
|
$24.03 M
|
$20.05 M
|
$16.02 M
|
$9.62 M
|
$5.14 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.46 M
|
$18.77 M
|
$20.95 M
|
$23.06 M
|
$24.03 M
|
$20.05 M
|
$16.02 M
|
$9.62 M
|
$5.14 M
|
| Other Expenses |
-$602.00 K
|
-$14.60 M
|
-$35.46 M
|
-$2.88 M
|
-$3.45 M
|
$0.00
|
-$245.00 K
|
-$103.00 K
|
$0.00
|
| Operating Expenses |
$27.86 M
|
$24.97 M
|
$22.35 M
|
$58.57 M
|
$87.89 M
|
$91.00 M
|
$74.92 M
|
$46.99 M
|
$18.84 M
|
| Cost And Expenses |
$28.73 M
|
$44.67 M
|
$57.81 M
|
$61.45 M
|
$91.33 M
|
$91.00 M
|
$74.92 M
|
$46.99 M
|
$18.84 M
|
| Interest Income |
$1.73 M
|
$422.00 K
|
$1.22 M
|
$100.00 K
|
$1.20 M
|
$3.29 M
|
$3.31 M
|
$1.06 M
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$3.56 M
|
$3.18 M
|
$1.29 M
|
$0.00
|
$3.31 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$867.00 K
|
$1.18 M
|
$2.18 M
|
$2.88 M
|
$3.45 M
|
$2.66 M
|
$2.18 M
|
$1.30 M
|
$153.00 K
|
| EBITDA |
-$25.12 M |
-$37.28 M |
-$38.73 M |
-$54.67 M |
-$89.10 M |
-$79.51 M |
-$74.22 M |
-$44.30 M |
-$28.07 M |
| EBITDA Ratio |
0
|
0
|
-164.11
|
-11.43
|
0
|
0
|
0
|
-32.06
|
0
|
| Operating Income Ratio |
0
|
0
|
-243.95
|
-11.84
|
0
|
0
|
0
|
-33
|
0
|
| Total Other Income/Expenses Net |
$5.18 M
|
$4.81 M
|
$13.10 M
|
-$4.06 M
|
-$2.51 M
|
$7.47 M
|
$3.07 M
|
$952.00 K
|
-$11.56 M
|
| Income Before Tax |
-$25.99 M
|
-$39.86 M
|
-$44.47 M
|
-$60.73 M
|
-$93.84 M
|
-$82.18 M
|
-$76.40 M
|
-$44.66 M
|
-$30.40 M
|
| Income Before Tax Ratio |
0
|
0
|
-188.43
|
-12.69
|
0
|
0
|
0
|
-32.31
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$25.99 M
|
-$39.86 M
|
-$44.47 M
|
-$60.73 M
|
-$93.84 M
|
-$82.18 M
|
-$76.40 M
|
-$44.66 M
|
-$30.40 M
|
| Net Income Ratio |
0
|
0
|
-188.43
|
-12.69
|
0
|
0
|
0
|
-32.31
|
0
|
| EPS |
-1.54 |
-2.7 |
-4.68 |
-10.9 |
-18.45 |
-17.16 |
-27.02 |
-129.91 |
-88.45 |
| EPS Diluted |
-1.54 |
-2.7 |
-4.68 |
-10.9 |
-18.45 |
-17.16 |
-27.02 |
-129.91 |
-88.45 |
| Weighted Average Shares Out |
$16.83 M
|
$14.77 M
|
$9.49 M
|
$5.58 M
|
$5.09 M
|
$4.36 M
|
$2.83 M
|
$343.73 K
|
$343.73 K
|
| Weighted Average Shares Out Diluted |
$16.83 M
|
$14.77 M
|
$9.49 M
|
$5.58 M
|
$5.09 M
|
$4.36 M
|
$2.83 M
|
$343.73 K
|
$343.73 K
|
| Link |
|
|
|
|
|
|
|
|
|
